Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | G6PD | P11413 | 2/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 6/20 | 0.34 |
| ▸ | HTR2A | P28223 | 3/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14853201 | 1.00 | KMT2A (0.39) | KMT2AMAPTMEN1NPC1RAB9A | |
| SCHEMBL15373215 | 1.00 | KMT2A (0.39) | KMT2AMAPTMEN1NPC1RAB9A | |
| SCHEMBL16133589 | 0.89 | KMT2A (0.47) | KMT2AMAPTMEN1NPC1RAB9A | |
| SCHEMBL5949738 | 0.89 | KMT2A (0.47) | KMT2AMAPTMEN1NPC1RAB9A | |
| SCHEMBL27325972 | 0.86 | TSHR (0.39) | KMT2AMAPTMEN1NPC1RAB9A | |
| SCHEMBL12424470 | 0.83 | BTK (0.55) | KMT2ABTKDRD2DRD3 | |
| SCHEMBL19156113 | 0.83 | BTK (0.55) | KMT2ABTKDRD2DRD3 | |
| SCHEMBL8168454 | 0.82 | TSHR (0.41) | KMT2AMEN1EPHX2JAK1TSHR | |
| SCHEMBL25117890 | 0.81 | ATM (0.46) | KMT2AMAPTMEN1NPC1RAB9A | |
| SCHEMBL22943926 | 0.81 | ATM (0.46) | KMT2AMAPTMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | KMT2A 1997/4885MAPT 4361/4885MEN1 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.